MedPath

Colestipol

Generic Name
Colestipol
Brand Names
Colestid
Drug Type
Small Molecule
CAS Number
26658-42-4
Unique Ingredient Identifier
K50N755924

Overview

Bile acid sequestrants like colestipol have been in use since the 1970s. And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as an adjunct therapy and the relatively physical nature of its pharmacological activity sometimes limits its usefulness. In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. Alternatively, colestipol predominantly elicits its activities within the gut environment because it undergoes little absorption and metabolism. The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.

Background

Bile acid sequestrants like colestipol have been in use since the 1970s. And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as an adjunct therapy and the relatively physical nature of its pharmacological activity sometimes limits its usefulness. In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. Alternatively, colestipol predominantly elicits its activities within the gut environment because it undergoes little absorption and metabolism. The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.

Indication

1.Ⅱa型高脂蛋白血症、冠心病危险性大而控制饮食治疗无效者。本品降低血浆总胆固醇和低密度脂蛋白胆固醇浓度,对血清甘油三酯浓度无影响或使之轻度升高,因此,对单纯甘油三酯升高者无效;2.胆管不完全阻塞所致的瘙痒。

Associated Conditions

  • Primary Hypercholesterolemia

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Carilion Materials Management
68151-4361
ORAL
1 g in 1 1
4/11/2016
Pharmacia & Upjohn Company LLC
0009-0260
ORAL
5 g in 5 g
11/29/2023
Physicians Total Care, Inc.
54868-0610
ORAL
1 g in 1 1
10/19/2010
Amneal Pharmaceuticals of New York LLC
0115-2142
ORAL
1 g in 1 1
11/11/2023
Amneal Pharmaceuticals of New York LLC
0115-5213
ORAL
5 g in 1 1
12/30/2023
ANI Pharmaceuticals, Inc.
62559-395
ORAL
1 g in 1 1
4/26/2023
Amneal Pharmaceuticals of New York LLC
0115-5211
ORAL
1 g in 1 1
9/20/2023
Greenstone LLC
59762-0450
ORAL
1 g in 1 1
11/18/2022
Pharmacia & Upjohn Company LLC
0009-0450
ORAL
1 g in 1 1
11/16/2022
Greenstone LLC
59762-0260
ORAL
5 g in 5 g
11/18/2022

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath